Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPIS: Salbutamol in Congenital Myopathy
NCT05099107Completed
- Sponsor
- Region Västra Götaland
- Start
- Oct 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of salbutamol in congenital myopathy (2 arms), sponsored by Region Västra Götaland. Primary endpoint: Motor Function Measure 32 at 19 months. Started Oct 2021; status: completed.
02
Drugs
salbutamol
03
Conditions
congenital myopathy
Beyond the preview
Go deeper on NCT05099107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099107.